MCID: PRN039
MIFTS: 40

Paraneoplastic Syndromes

Categories: Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Paraneoplastic Syndromes

MalaCards integrated aliases for Paraneoplastic Syndromes:

Name: Paraneoplastic Syndromes 55 56 74

Classifications:



External Ids:

UMLS 74 C0030472

Summaries for Paraneoplastic Syndromes

NINDS : 55 Paraneoplastic syndromes are a group of rare disorders that are triggered by an abnormal immune system response to a cancerous tumor known as a "neoplasm." Paraneoplastic syndromes are thought to happen when cancer-fighting antibodies or white blood cells (known as T cells) mistakenly attack normal cells in the nervous system. These disorders typically affect middle-aged to older people and are most common in individuals with lung, ovarian, lymphatic, or breast cancer. Neurologic symptoms generally develop over a period of days to weeks and usually occur prior to the tumor being discovered. These symptoms may include difficulty in walking or swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs, and vertigo or dizziness. Paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome, stiff-person syndrome, encephalomyelitis, myasthenia gravis, cerebellar degeneration, limbic or brainstem encephalitis, neuromyotonia, opsoclonus, and sensory neuropathy.

MalaCards based summary : Paraneoplastic Syndromes is related to small cell cancer of the lung and oncogenic osteomalacia, and has symptoms including paraneoplastic opsoclonus ataxia An important gene associated with Paraneoplastic Syndromes is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and HIF-1 signaling pathway. The drugs Mitoxantrone and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and bone, and related phenotypes are Decreased melanin production and respiratory system

Wikipedia : 77 A paraneoplastic syndrome is a syndrome (a set of signs and symptoms) that is the consequence of cancer... more...

Related Diseases for Paraneoplastic Syndromes

Diseases related to Paraneoplastic Syndromes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 small cell cancer of the lung 29.8 ENO2 RCVRN
2 oncogenic osteomalacia 29.7 FGF23 PTHLH
3 cancer-associated retinopathy 29.4 ENO2 RCVRN
4 dysgerminoma 29.2 ENO2 PTHLH
5 dysgerminoma of ovary 29.2 ENO2 PTHLH
6 paraneoplastic cerebellar degeneration 11.6
7 poems syndrome 11.3
8 adenoma 11.3
9 leiomyoma 11.3
10 autoimmune encephalitis 11.3
11 carcinoid syndrome 11.3
12 multicentric reticulohistiocytosis 11.0
13 leiomyomatosis 11.0
14 adrenal adenoma 11.0
15 peritonitis 11.0
16 small cell carcinoma of the bladder 11.0
17 lung cancer 10.4
18 renal cell carcinoma, nonpapillary 10.2
19 lymphoma 10.2
20 squamous cell carcinoma 10.1
21 thymoma 10.1
22 breast cancer 10.1
23 ovarian cancer 10.1
24 dermatomyositis 10.1
25 adenocarcinoma 10.1
26 neutrophilia, hereditary 10.1 IL6 PTHLH
27 small cell carcinoma 10.1
28 hepatocellular carcinoma 10.0
29 neuroblastoma 10.0
30 prostate cancer 10.0
31 prostate cancer, hereditary, 8 10.0
32 prostate cancer, hereditary, 6 10.0
33 leukemia 10.0
34 cerebellar degeneration 10.0
35 myasthenia gravis 10.0
36 lung cancer susceptibility 3 10.0
37 lambert-eaton myasthenic syndrome 10.0
38 encephalitis 10.0
39 myasthenia gravis congenital 10.0
40 metaphyseal chondrodysplasia, jansen type 10.0 FGF23 PTHLH
41 iron deficiency anemia 10.0 FGF23 IL6
42 parathyroid gland disease 10.0 FGF23 PTHLH
43 mineral metabolism disease 9.9 FGF23 PTHLH
44 myositis 9.9
45 thymoma, familial 9.9
46 osteomalacia 9.9
47 nephrotic syndrome 9.9
48 melanoma 9.9
49 thrombocytosis 9.9
50 vasculitis 9.9

Graphical network of the top 20 diseases related to Paraneoplastic Syndromes:



Diseases related to Paraneoplastic Syndromes

Symptoms & Phenotypes for Paraneoplastic Syndromes

UMLS symptoms related to Paraneoplastic Syndromes:


paraneoplastic opsoclonus ataxia

GenomeRNAi Phenotypes related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased melanin production GR00056-A 8.62 ENO2 FGF23

MGI Mouse Phenotypes related to Paraneoplastic Syndromes:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 8.92 ENO2 FGF23 IL6 PTHLH

Drugs & Therapeutics for Paraneoplastic Syndromes

Drugs for Paraneoplastic Syndromes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
8 Topoisomerase Inhibitors Phase 4,Phase 2
9 Analgesics Phase 4
10 Antiviral Agents Phase 4,Phase 2
11 Interferon-beta Phase 4
12 interferons Phase 4,Phase 2
13 Anti-Infective Agents Phase 4,Phase 2
14 Adjuvants, Immunologic Phase 4
15 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
16 Antacids Phase 4,Phase 3,Phase 2
17 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2
18
Zoledronic Acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 118072-93-8 68740
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
23
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
24
Amifampridine Approved, Investigational Phase 3,Phase 2,Not Applicable 54-96-6
25
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
26
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
27
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
29
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
30 Ibandronic Acid Phase 3
31 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2,Not Applicable
32 Prednisolone acetate Phase 3
33 Anti-Inflammatory Agents Phase 3,Not Applicable
34 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Autonomic Agents Phase 3,Phase 1,Phase 2
36 Neuroprotective Agents Phase 3
37 glucocorticoids Phase 3,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Protective Agents Phase 3
40 Methylprednisolone Acetate Phase 3
41 Antiemetics Phase 3
42 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 3,Phase 2,Phase 1
45 Neuromuscular Agents Phase 3,Phase 2,Not Applicable
46 Potassium Channel Blockers Phase 3,Phase 2,Not Applicable
47 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
48 Antineoplastic Agents, Hormonal Phase 3,Phase 2
49 Antibodies Phase 3,Phase 1,Phase 2
50 Immunoglobulins Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
4 Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
5 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
6 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3 zoledronic acid
7 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
8 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
9 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
10 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
11 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3 amifampridine phosphate;Placebo
12 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone Withdrawn NCT00301886 Phase 3 ibandronate;zoledronate
15 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
16 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2 anti-CD20 (Rituximab)
17 Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases Completed NCT00060138 Phase 1, Phase 2 zoledronic acid
18 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
19 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
20 MC-5A for Chemotherapy Induced Peripheral Neuropathy Completed NCT01261780 Phase 2 Sham device
21 Effectiveness of Rituximab in Pediatric OMS Patients. Completed NCT00244361 Phase 1, Phase 2 rituximab
22 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed NCT00896454 Phase 2 denosumab
23 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
24 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
25 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
26 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
27 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
28 Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Not yet recruiting NCT03887273 Phase 1, Phase 2
29 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Not yet recruiting NCT03274375 Phase 2 IA session;Rituximab
30 IVIG Treatment for Refractory Immune-Related Adult Epilepsy Terminated NCT01545518 Phase 2 IVIG
31 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
32 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
33 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
34 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
35 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
36 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
37 One Week Comparison Study of PTH and PTHrP Infusions Withdrawn NCT01333267 Phase 1 Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36)
38 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
39 Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Unknown status NCT01660308
40 Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Unknown status NCT00458796 Not Applicable zoledronic acid
41 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Unknown status NCT02559089
42 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Unknown status NCT02443350
43 Maintenance Plasma Exchange for Neuromyelitis Optica Unknown status NCT01500681
44 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326 Not Applicable Tacrolimus
45 Studies of Neurological Paraneoplastic Syndromes Completed NCT00587106
46 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Completed NCT00580788 Early Phase 1 PTHrP (1-36)
47 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950 Not Applicable
48 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Completed NCT01865578 Not Applicable
49 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
50 Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Completed NCT00806182

Search NIH Clinical Center for Paraneoplastic Syndromes

Genetic Tests for Paraneoplastic Syndromes

Anatomical Context for Paraneoplastic Syndromes

MalaCards organs/tissues related to Paraneoplastic Syndromes:

42
Lung, Breast, Bone, T Cells, Spinal Cord, Eye, Pancreas

Publications for Paraneoplastic Syndromes

Articles related to Paraneoplastic Syndromes:

(show top 50) (show all 321)
# Title Authors Year
1
Cutaneous paraneoplastic syndromes. ( 30736994 )
2019
2
Paraneoplastic syndromes-"keys" to histopathological diagnoses and appropriate therapy. ( 30876819 )
2019
3
Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. ( 30876820 )
2019
4
Review of paraneoplastic syndromes in children. ( 30877339 )
2019
5
Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. ( 30910348 )
2019
6
Paraneoplastic syndromes in ophthalmology. ( 29784239 )
2018
7
Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. ( 29429069 )
2018
8
Paraneoplastic, Syndromes ( 29939667 )
2018
9
Advanced-Stage Thymoma Associating Multiple Paraneoplastic Syndromes with Good Response to Oral Corticosteroids and Topical Tacrolimus. ( 29887166 )
2018
10
Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma. ( 29318181 )
2018
11
Endocrine paraneoplastic syndromes in lung cancer. ( 29968234 )
2018
12
Uncommon reasons of the digestive tract-related paraneoplastic syndromes in children with neuroblastic tumors: three case reports. ( 29692663 )
2018
13
Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications. ( 30498610 )
2018
14
Neurological paraneoplastic syndromes: an update. ( 30124520 )
2018
15
Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. ( 30280284 )
2018
16
Immunopathogenesis of ophthalmological paraneoplastic syndromes: Recent findings. ( 30289210 )
2018
17
Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. ( 28767671 )
2017
18
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. ( 28285701 )
2017
19
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. ( 29191778 )
2017
20
Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes. ( 28160197 )
2017
21
Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. ( 28736272 )
2017
22
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. ( 28838389 )
2017
23
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. ( 28285700 )
2017
24
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. ( 28285683 )
2017
25
Paraneoplastic syndromes associated with gynecological cancers: A systematic review. ( 28655412 )
2017
26
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. ( 28838388 )
2017
27
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016
28
Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26666237 )
2016
29
Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. ( 26711581 )
2016
30
Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases. ( 27795759 )
2016
31
Reply to: "Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients": By BetA1l Vatankulu, Sabire Yilmaz Aksoy, Sait Sager, Metin HalaAs. ( 26669307 )
2016
32
The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer. ( 27413699 )
2016
33
Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. ( 27287529 )
2016
34
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. ( 26914818 )
2016
35
Paraneoplastic Syndromes in Neuro-Ophthalmology. ( 26172160 )
2015
36
Update on neurological paraneoplastic syndromes. ( 26335665 )
2015
37
Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. ( 25829659 )
2015
38
A rare thymoma case with seven paraneoplastic syndromes. ( 26770603 )
2015
39
Paraneoplastic syndromes in olfactory neuroblastoma. ( 26199564 )
2015
40
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26194717 )
2015
41
Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma. ( 26199695 )
2015
42
Paraneoplastic Syndromes in Palliative Care: A literature review from a nursing perspective. ( 26514024 )
2015
43
Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. ( 26506668 )
2015
44
Hyperamylasaemia and dual paraneoplastic syndromes in small cell lung cancer. ( 24048720 )
2014
45
Lung squamous carcinoma with two paraneoplastic syndromes -Dermatomyositis and Lambert-Eaton myasthenic syndrome. ( 25335449 )
2014
46
Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas: clinical manifestations and prognostic significance. ( 25351497 )
2014
47
Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes. ( 24859505 )
2014
48
Paraneoplastic syndromes in rheumatology. ( 25136782 )
2014
49
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. ( 25065928 )
2014
50
Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. ( 24480222 )
2014

Variations for Paraneoplastic Syndromes

Expression for Paraneoplastic Syndromes

Search GEO for disease gene expression data for Paraneoplastic Syndromes.

Pathways for Paraneoplastic Syndromes

Pathways related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.98 FGF23 PTHLH
2 10.62 ENO2 IL6

GO Terms for Paraneoplastic Syndromes

Cellular components related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.92 ENO2 FGF23 IL6 PTHLH

Biological processes related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 8.8 FGF23 IL6 PTHLH

Molecular functions related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.62 FGF23 IL6

Sources for Paraneoplastic Syndromes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....